Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery. 2023

Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada.

Continuous factor VIII (FVIII) or factor IX (FIX) infusions are commonly used for patients with hemophilia A (HA) or B (HB) undergoing surgery to secure perioperative hemostasis. To describe differences between the initial recovery and subsequent FIX and FVIII levels, and describe clinical outcomes among HB and HA patients receiving perioperative continuous infusion (CI) of recombinant FVIII and FIX concentrates. Retrospective chart review was conducted on 8 consecutive patients with HB and 7 consecutive patients with HA who underwent major surgery between 2014 and 2018 and received continuous infusions of standard half-life factor concentrate. Median initial bolus dose per kilogram was higher for HB compared to HA patients [90.8 (IQR 78.0-98.7) vs. 52.1 (IQR 48.6-55.6) IU/kg], while initial CI dose-rates were similar [4.3 (IQR 3.8-4.6) vs. 4.2 (IQR 3.8-4.4) IU/kg/h]. Median post-bolus recovery was higher for FVIII compared to FIX [1.70 (IQR 1.23-1.75) vs. 0.88 (IQR 0.75-1.00) IU/mL]. Median factor levels also were higher for FVIII on post-operative days 1 to 3. HB patients had greater mean intraoperative estimated blood loss [285.7 (range 0-1000) vs. 142.8 (range 0-400) mL] and longer median length of hospital stay [9 (IQR 8-12) vs. 5 (IQR 4-6.5) days]. Our initial evidence suggests greater in vivo yield of rFVIII compared to rFIX in the perioperative setting. We identified poorer clinical outcomes in this small cohort of perioperative HB patients indicating that they may benefit from a higher CI rate for adequate surgical hemostatic coverage.

UI MeSH Term Description Entries
D002836 Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008) Christmas Disease,Factor IX Deficiency,Deficiency, Factor IX,F9 Deficiency,Haemophilia B,Hemophilia B Leyden,Hemophilia B(M),Plasma Thromboplastin Component Deficiency,Bs, Hemophilia,Deficiencies, F9,Deficiencies, Factor IX,Deficiency, F9,Disease, Christmas,F9 Deficiencies,Factor IX Deficiencies,Haemophilia Bs,Hemophilia Bs,Hemophilia Bs (M)
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006490 Hemostatics Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. Antihemorrhagic,Hemostatic,Antihemorrhagics
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016063 Blood Loss, Surgical Loss of blood during a surgical procedure. Hemorrhage, Surgical,Surgical Blood Loss,Surgical Hemorrhage,Surgical Blood Losses,Surgical Hemorrhages
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
November 2018, Journal of thrombosis and haemostasis : JTH,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
August 1986, Computer methods and programs in biomedicine,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
March 2006, Haemophilia : the official journal of the World Federation of Hemophilia,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
August 2018, International journal of hematology,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
February 1971, JAMA,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
January 2008, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
January 2016, Seminars in hematology,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
April 1978, Blood,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
September 1982, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Brandon Tse, and Rosane Nisenbaum, and Georgina Floros, and Aziz Jiwajee, and Jerome Teitel, and Michelle Sholzberg
August 2023, Research and practice in thrombosis and haemostasis,
Copied contents to your clipboard!